Navigation Links
Gene therapy protects mice from lethal heart condition, MU researchers find
Date:8/20/2014

COLUMBIA, Mo. A new gene therapy developed by researchers at the University of Missouri School of Medicine has been shown to protect mice from a life-threatening heart condition caused by muscular dystrophy.

"This is a new therapeutic avenue," said Yi Lai, Ph.D., the leading author of the study and assistant research professor in the MU School of Medicine's Department of Molecular Microbiology and Immunology. "This is just a first step, but we hope this could lead to a treatment for people with this devastating heart condition, which is a leading cause of death for people with Duchenne muscular dystrophy."

About one in 3,500 children, mostly boys, are born with Duchenne muscular dystrophy (DMD). They experience a progressive wasting away of muscles, starting in the legs and pelvis. Children with DMD have difficulty walking, and most need wheelchairs by age 12.

As DMD depletes the skeletal muscles, it also causes the heart to decay. A weakened heart kills up to 40 percent of people with DMD, usually by their 20s or early 30s. DMD originates with mutations in a single gene. For more than two decades, researchers have explored using gene therapy, an experimental treatment, to replace the flawed gene with a healthy copy.

The recent MU study, however, did not try to replace the faulty gene. The researchers targeted a different gene one involved with the heart's built-in system for responding to heart attacks and other emergencies.

This targeted gene expresses a protein called nNOS. During short-term stresses, nNOS activates briefly to help regulate the heart. The MU researchers altered the gene to enable more efficient transfer of the nNOS gene to mouse hearts.

Seven months after the gene therapy, the mice who received the treatment showed significantly improved overall heart health. On most disease indicators, the researchers found that the treatment protected their hearts from the damage of DMD.

"The study showed for the first time that a modified nNOS gene could be delivered through gene therapy to protect the hearts of mice from Duchenne muscular dystrophy," said Dongsheng Duan, Ph.D., co-author of the study and Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine.

"Since nNOS protects against multiple heart diseases, this method could one day be extended to the treatment of other heart diseases, such as heart failure or a heart attack," Duan said.

The technique is in an early stage of development and will require more research before potential applications in humans are explored.


'/>"/>

Contact: Derek Thompson
thompsonder@health.missouri.edu
573-882-3323
University of Missouri-Columbia
Source:Eurekalert  

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
3. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
4. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
5. Researchers discover novel therapy for Crohns disease
6. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
7. Cell therapy using patients own bone marrow may present option for heart disease
8. Harmless human virus may be able to boost the effects of chemotherapy
9. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
10. Nanobubbles plus chemotherapy equals single-cell cancer targeting
11. New data suggests interferon-free therapy around the corner for HCV patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy protects mice from lethal heart condition, MU researchers find
(Date:5/14/2019)... ... 2019 , ... IMMUNE 3D®, a privately held biotechnology company, ... autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, ... , IMMUNE 3D®’s proprietary platform aims to study factors that affect immune ...
(Date:5/9/2019)... ... May 09, 2019 , ... Akadeum Life Sciences today ... on its microbubble technology. Unlike magnetic-based products, microbubbles use buoyancy to gently separate ... customers who participated in an early access program has been very encouraging and ...
(Date:5/8/2019)... ... 08, 2019 , ... MMS Holdings – an award-winning, data-focused ... Medrio , the leading provider of eClinical technology for small to mid-sized ... to position high-quality CRO services with Medrio’s fast and easy-to-use eClinical products, MMS ...
Breaking Biology News(10 mins):
(Date:5/7/2019)... ... May 06, 2019 , ... "The ... growing number of repositories being asked to store cellular products being used ... of contributors who are world leaders, who have shared their expertise in building ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, ... Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) ... estimated that 6.3 million Americans will have glaucoma, with black Americans having the ...
(Date:5/2/2019)... ... , ... The centuries old practice of brewing beer thrives today across a ... even home brewing clubs scattered across the nation. , But proper beer brewing, ... produce a superb product. Students at South Dakota School of Mines & Technology ...
(Date:5/2/2019)... ... May 02, 2019 , ... ... will present results documenting discrepancies between U.S. insurer policies for genetic testing and ... risk for hereditary breast and ovarian cancer (HBOC). , Jill S. ...
Breaking Biology Technology: